MSD Partners’s Ocular Therapeutix OCUL Stock Holding History

MSD Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,016,302	Closed	-$4.09M	–	87
2022 Q2	$4.09M	Buy	+1,016,302	New	+$3.84M	0.25%	28

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $545M AUM 33.4% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

MSD Partners's OCUL Position: Q3 2022 in Review

MSD Partners sold out of Ocular Therapeutix (OCUL) in Q3 2022, closing a stake of 1,016,302 shares — an estimated $4.09M sold.

MSD Partners first reported a position in OCUL in Q2 2022 and held it in 1 quarter. The position peaked at $4.09M in Q2 2022. 130 funds tracked by Wall St. Rank hold OCUL as of Q3 2022.

MSD Partners reported no remaining Ocular Therapeutix position as of Q3 2022 after selling out during the quarter.
MSD Partners sold 1,016,302 Ocular Therapeutix shares in Q3 2022, an estimated $4.09M.
MSD Partners first reported a position in Ocular Therapeutix in Q2 2022 and held it in 1 quarter.
MSD Partners's Ocular Therapeutix position peaked at $4.09M in Q2 2022.
130 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q3 2022.

Based on MSD Partners's 13F filing for Q3 2022, filed 14 Nov 2022.